Role of Chorioallantoic Model in the treatment of renal and bladder carcinoma

Abstract

Non-invasive bladder cancer cell lines (AY27) and renal cancer cell lines (RCC) are utilized in in vitro models for experimentation. To gain better insight of cancer mechanisms within the tumor microenvironment, in vivo models are more appropriate. The Chorioallantoic Model (CAM) addresses some limitations in vitro and allow for further experimentation. We wished to see whether the CAM could be used with bladder and renal cancer cell lines as a means to examine potential therapies in vivo. The CAM model provides a quick and reproducible means for experimentation. AY27 and RCC with Hippel-Lindau mutated renal cancer cell line (RCC-VHL) were injected as boli into the CAM to investigate tumor development and progression. RCCs were labelled with Green Fluorescent Proteins (GFP) whereas AY27s were non-fluorescent. In ovo models were simultaneously conducted to examine tumor growth in both AY27 and RCC cell lines. Microscopy was used to indirectly monitor tumor growth through degree of fluorescence for RCCs and standard light microscopy were used to monitor tumor growth of AY27s. In AY27-boli injected CAMs, we observed significant increase in tumor size after 9 days. In RCC-VHL injected CAMs, we observed fluorescence and tumor growth to a lesser extent than in AY27 models. The observations are evidence for potential growth of tumors in the in ovo models. Growth of tumors in ovo contradicts previous evidence of scar tissue due to macrophage attack of AY27 and RCC-VHL. Thus, these observations provide potential experimentation model for bladder and renal cancer treatment.

* Indicates faculty mentor